A case of posttransplantation lymphoproliferative disease developed in renal transplant recipient and treated with rituximab.
- Author:
Ui Soon PARK
1
;
Chan Bum CHOI
;
In Soon KIM
;
Il Young CHOI
;
Jong Myung KANG
;
Chan Kum PARK
;
Myung Ju AHN
Author Information
1. Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea. ahnmj@hanyang.ac.kr
- Publication Type:Case Report
- Keywords:
Posttransplant lymphoproliferative disorder;
Rituximab;
Renal transplantation
- MeSH:
Allografts;
Drug Therapy;
Herpesvirus 4, Human;
Immunosuppression;
Interferons;
Kidney Transplantation;
Liver;
Lymphoproliferative Disorders;
Transplantation*;
Transplants;
Rituximab
- From:Korean Journal of Medicine
2004;67(1):94-99
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Posttransplant lymphoproliferative disorder (PTLD) are among the most serious and potentially fatal complications of chronic immunosuppression in organ transplant recipient and also the most common malignancies, accounting for 21 percent of all malignancies in organ transplants versus 5 percent of malignancies in the general population. PTLD is associated with immunosuppression and Epstein Barr virus (EBV). Treatment modality of PTLD includes antiviral agent, interferon, intensive chemotherapy and monoclonal antibody. Choice of treatment modality depends on clinical presentation of PTLD. We report here a case of PTLD involving liver and renal allograft treated with rituximab.
